Wirdatun Nafisah

Wirdatun Nafisah

Auto-generated profile, based on publicly available information

Wirdatun Nafisah

Universitas Negeri Surabaya

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
ARAbu Hanifah Ramadhani
Abu Hanifah Ramadhani
WNWirdatun Nafisah
Wirdatun Nafisah
HIHary Isnanto
Hary Isnanto
TSTri Kurniawati Sholeha
Tri Kurniawati Sholeha
YJYoga Dwi Jatmiko
Yoga Dwi Jatmiko
MRMuhaimin Rifa'I
Muhaimin Rifa'I
Background: The carcinogenic substance 7,12-Dimethylbenz[a]anthracene (DMBA) was commonly used to induce tumor formation in rodents. The development of tumor may trigger higher expression of pro-inflammatory cytokines, which in turn supports tumor progression. In this study, we examined the efficacy of Cyperus rotundus extract (CRE) that was reported to have anti-inflammatory properties. We focused on investigating the levels of activated T lymphocytes and the pro-inflammatory cytokines expressed by macrophages. Methods: Female BALB/c were injected with DMBA subcutaneously. The DMBA exposed mice were given CRE orally in three different doses; 63.33, 158.4, and 316.8 mg/kg. After 14 days, the levels of activated T lymphocytes and pro-inflammatory cytokines were analyzed using flow cytometry. Graphical analysis was done with FlowJo v10 and followed by statistical analysis. Results: The treatment of CRE reduced the population of CD4 and CD8 T cells. The number of activated CD4 and CD8 T cells were also significantly suppressed. The population of macrophages marked by CD11b cells was significantly reduced. Finally, the CRE treatment suppressed the levels of TNF-α, IFN-γ, IL-1β, and IL-6 expressed by macrophages. Conclusion: Our findings suggest that CRE could be a potential agent useful in therapeutic approaches for curing the disease caused by aberrant cells.

5 April 2023 in F1000Research
Verified
Journal Article
Open access
PDF file
WNWirdatun Nafisah
Wirdatun Nafisah
ANAlexander Patera Nugraha
Alexander Patera Nugraha
ANAditya Nugroho
Aditya Nugroho
ASAndi Isti Sakinah
Andi Isti Sakinah
DNDuano Sapta Nusantara
Duano Sapta Nusantara
TNTengku Natasha Eleena Binti Tengku Ahmad Noor
Tengku Natasha Eleena Binti Tengku Ahmad Noor
Background: Utilizing the bioactive compounds found in pigmented rice might significantly reduce the risk of breast cancer. This study aims to systematically review existing literature on the benefit of Asian pigmented rice bioactive compounds and their implication in breast cancer. Methods: Searches of the literature were conducted in two databases (Scopus and PubMed) for a systematic review. The keywords resulted in a total of 407 articles, consisting of 103 PubMed and 304 Scopus articles. 32 manuscripts were excluded because the article was over 10 years old. After excluding book chapters and non-English languages, we had 278 potential articles to be reviewed. After checking and screening the title and abstract and eliminating duplicate articles, then 66 articles were obtained. After the selection and elimination of the full-text manuscripts, finally 10 of them which met the inclusion criteria. Result: The included studies in this review were entirely based in Asia. The year of publication ranged from 2013 to 2020. Half of included studies used black rice extract, two used red jasmine rice extracts, and three used Korean rice extracts (black, red, dark purple and brown rice). All studies were conducted in vitro and three studies were compared with in vivo tests on female mice. The pigmented rice is mainly black, red, and dark purple rice, and contains a variety of peonidin-3-glucoside, cyanidin-3-glucoside, γ-oryzanol, γ-tocotrienol, proanthocyanidin, cinnamic acid, and anthocyanins that may act as pro-apoptotic, anti-proliferative, and anti-metastasis of the breast cancer cells. Conclusion: Pigmented rice is a beneficial food which possessed bioactive compounds that may have significant potential concerning a breast cancer.

1 July 2023 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
WNWirdatun Nafisah
Wirdatun Nafisah
NWNadia Wahyuningsih
Nadia Wahyuningsih
MMMuhammad Faiz Maulana
Muhammad Faiz Maulana
SAShella Zahra Kumala Azmi
Shella Zahra Kumala Azmi
MRMuhaimin Rifa’i
Muhaimin Rifa’i
MDMuhammad Sasmito Djati
Muhammad Sasmito Djati
J. Pharm. Pharmacogn. Res., vol. 11, no. 4, pp. 674-682, Jul-Aug 2023. DOI: https://doi.org/10.56499/jppres23.1604_11.4.674 Original Article Cyperus rotundus L. rhizome extract modulates immune system and induces apoptotic in 4T1-tumor bearing mice [Extracto de rizoma de Cyperus rotundus L. modula el sistema inmunitario e induce la apoptosis en ratones portadores de tumores 4T1] Wirdatun Nafisah1,2, Nadia Wahyuningsih3, Cyperus rotundus L. rhizome extract modulates immune system and induces apoptotic in 4T1-tumor bearing mice.

1 January 2026 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Closed access
NANa’iLah I. Alifiyah
Na’iLah I. Alifiyah
WNWirdatun Nafisah
Wirdatun Nafisah
RRRizki Rizki
Rizki Rizki
AAArie Aryanto
Arie Aryanto
HZHikmah Zikriyani
Hikmah Zikriyani
Context: Breast cancer remains the most prevalent malignancy among women and presents therapeutic challenges due to adverse effects associated with conventional treatments. Cuminum cyminum seeds extract (CCSE), recognized for its antioxidant and antibacterial properties, has been investigated as a potential source of alternative therapeutic agents. Aims: To profile the phytochemical constituents of CCSE using GC-MS and to evaluate the predicted interactions of selected compounds with breast cancer–related proteins through in silico molecular docking analyses. Methods: The ethanolic extract of CCSE was analyzed by GC-MS, yielding the identification of 269 phytoconstituents. From these, three bioactive compounds—carvone, p-cymene, and linalool—were selected for further evaluation. Their potential anticancer activities were predicted using the PASS and CLC-Pred platforms, while drug-likeness properties were assessed through SwissADME. In silico toxicity profiles were also predicted using the ProTox-3.0 webserver. Pathway interactions were analyzed using the STITCH database. Molecular docking studies were then performed with AutoDock Vina in PyRx against Erα, MDM2, HER2, and caspase-3, with doxorubicin used as a reference drug. Results: The selected compounds were predicted to have potential anticancer activity against breast cancer through multiple mechanisms, including regulation of apoptosis. Carvone and p-cymene showed favorable predicted binding affinities for MDM2 and HER2 compared with doxorubicin, suggesting possible tumor-suppressive effects. Linalool was predicted to interact with MDM2, caspase-3, ERα, and HER2, with some affinities comparable to those of doxorubicin, indicating a potential role in modulating apoptosis pathways and receptor-mediated signaling. These findings provide preliminary in silico evidence of the breast cancer–related anticancer potential of CCSE bioactive compounds relative to doxorubicin, and further experimental validation is required. Conclusions: These findings suggest that CCSE-derived compounds may possess potential anticancer activity against breast cancer; however, further in vitro and in vivo validation is necessary.

15 February 2026 in Biointerface Research in Applied Chemistry
Verified
Journal Article
Open access
WNWirdatun Nafisah
Wirdatun Nafisah
Gusnia Meilin GholamGusnia Meilin Gholam
Gusnia Meilin Gholam
MDMaheswari Alfira Dwicesaria
Maheswari Alfira Dwicesaria
ESElma Sajidah
Elma Sajidah
FSFatima Shahid
Fatima Shahid
IAI Made Artika
I Made Artika
Cancer remains a major health issue, and Bcl-2 inhibits apoptosis. This study explored the phytochemicals of Codiaeum variegatum as potential Bcl-2 inhibitors. Receptor–ligand docking was conducted with YASARA, followed by 300 ns MD using AMBER14. ADME and DFT analyses were used to characterize the pharmacokinetics and electronic properties of the inhibitor candidates. The large-scale data generated from the 300-nanosecond MD simulations were further processed to map the energy landscapes using PCA and DCCM analysis in R Studio. We successfully applied the QM-AM1 method to the preparation and execution of molecular docking studies. Among the 17 phytochemical compounds isolated from C. variegatum, taraxerol demonstrated the most promising binding energy, with a docking score of −8.868 kcal/mol, which is comparable to that of the co-crystallized reference ligand, venetoclax. Taraxerol also satisfied the ADME criteria based on Lipinski’s Rule of Five, with only a single rule violation, and DFT calculations confirmed its stability, exhibiting an energy gap of −0.1805 eV. Furthermore, a 300 ns MD simulation revealed that the binding energy of taraxerol, computed using the MM-PBSA method, was more favorable than that of venetoclax, with taraxerol yielding 303.235 kJ/mol in complex with Bcl-2, compared to 291.115 kJ/mol for venetoclax. PCA and DCCM analyses additionally supported the dynamic stability of taraxerol as a potential Bcl-2 inhibitor. Although ADME predictions suggest a favorable safety profile, further in vitro and in vivo validation is required to substantiate its therapeutic potential.

1 January 2026 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Closed access
KSKhalish Arsy Al Khairy Siregar
Khalish Arsy Al Khairy Siregar
FMFachrur Rizal Mahendra
Fachrur Rizal Mahendra
AMAlfa Marzelino
Alfa Marzelino
DIDwi Wahyu Indriani
Dwi Wahyu Indriani
JTJoko Pebrianto Trinugroho
Joko Pebrianto Trinugroho
ASAnissa SARI
Anissa SARI
Context: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, highlighting the need for novel targeted therapies. Clitoria ternatea (CT), a medicinal plant with diverse bioactive compounds, shows promising anticancer potential in preclinical studies, yet its molecular mechanisms in CRC remain poorly understood. Aims: To elucidate the anti-CRC mechanisms and potential therapeutic targets of CT compounds through integrated bioinformatics and network pharmacology approaches. Methods: Active CT compounds were obtained from the literature and screened for drug-likeness. CRC-associated targets from GeneCards were intersected with CT-related targets to identify overlapping candidates. Overlapping targets were analyzed using network pharmacology, Gene Ontology (GO), and KEGG pathway enrichment. Hub genes were validated through mRNA expression, pathological stage correlations, and molecular docking, followed by 100-ns molecular dynamics simulations to assess binding stability. Results: Thirty-two CT compounds and eleven potential CRC-related targets were identified, with CCND1 and HSP90AB1 emerging as central hub genes linked to the PI3K/AKT and CRC signaling pathways. Ellagic acid exhibited the strongest binding affinity to CCND1 (−8.3 kcal/mol) and HSP90AB1 (−9.5 kcal/mol), and maintained conformational stability during simulations, outperforming control ligands. These findings highlight the multi-target therapeutic potential of CT in CRC. Further in vitro studies are needed to investigate CCND1 and HSP90AB1 expression, cell proliferation, and apoptosis in CRC models. Conclusions: CT exhibits multi-target anti-CRC potential by modulating CCND1 and HSP90AB1, suggesting a mechanistic link to the PI3K/AKT signaling pathway. These results support further validation (in vitro and in vivo studies) of CT and ellagic acid as potential adjuvant CRC therapies.